McKesson Corporation is acquiring Precision Medicine Group for $2.25 billion, significantly expanding its drug development and commercialisation capabilities. The healthcare wholesaler, which ranks eighth on the Fortune 500 list, will fold privately
More
The patient support landscape in 2026 looks fundamentally different from what existed even a decade ago, driven by rapid shifts in specialty medicine. Manufacturers have significantly expanded investment in digital engagement, specialty
More
Johnson & Johnson has secured a significant regulatory win, with the FDA approving its therapy Imaavy for a second indication targeting a rare and life-threatening blood condition. The approval covers Imaavy, known
More
Cellares, the automated cell therapy manufacturer that has risen rapidly since its 2019 founding in South San Francisco, is now confronting a significant business setback. Co-founder and CEO Fabian Gerlinghaus revealed over
More
Eli Lilly (LLY) has released a new campaign spotlighting the decades-long struggles of older obesity patients and its Medicare GLP-1 Bridge program. The campaign, titled “A Life Covered,” is the latest short
More
Health and Human Services Secretary Robert F. Kennedy Jr. is pushing to overhaul how the United States develops and categorises its childhood vaccine recommendations. Kennedy posted a Request for Information on Friday,
More
Swedish drugmaker Hansa Biopharma is positioning itself for a potential US stock market listing as a critical regulatory verdict on its kidney transplant drug draws near. The company submitted draft forms to
More
Merck and AstraZeneca have suffered fresh legal defeats in their efforts to block the government’s Medicare drug price negotiation programme under the Inflation Reduction Act. The U.S. Court of Appeals for the
More
Independent pharmacies across the United States are under mounting financial strain, with a significant portion of owners now weighing whether to shut their businesses entirely. A recent National Community Pharmacists Association survey
More
Daiichi Sankyo is promoting Ken Keller to lead a newly created globally integrated commercialization unit as part of its ambition to become a top five oncology company by 2035. The Japanese drugmaker
More